43 related articles for article (PubMed ID: 34959168)
1. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers.
Zhong R; Ling X; Cao S; Xu J; Zhang B; Zhang X; Wang H; Han B; Zhong H
ESMO Open; 2022 Feb; 7(1):100334. PubMed ID: 34959168
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E; Rodríguez-Abreu D; Simó M; Massutí B; Juan O; Huidobro G; López R; De Castro J; Estival A; Mosquera J; Sullivan I; Felip E; Blasco A; Guirado M; Pereira E; Vilariño N; Navarro V; Bruna J
J Clin Oncol; 2023 Oct; 41(28):4478-4485. PubMed ID: 37603816
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Leonetti A; Perrone F; Puntoni M; Maglietta G; Bordi P; Bria E; Vita E; Gelsomino F; De Giglio A; Gelibter A; Siringo M; Mazzoni F; Caliman E; Genova C; Bertolini F; Guaitoli G; Passiglia F; Delcuratolo MD; Montrone M; Cerea G; Pasello G; Roca E; Belluomini L; Cecere FL; Guida A; Manzo A; Adamo V; Rastelli F; Bulotta A; Citarella F; Toschi L; Zoratto F; Cortinovis DL; Berardi R; Follador A; Carta A; Camerini A; Salerno F; Silva RR; Baldini E; Cortellini A; Brighenti M; Santoni M; Malorgio F; Caminiti C; Tiseo M
Eur J Cancer; 2024 May; 202():114006. PubMed ID: 38489861
[TBL] [Abstract][Full Text] [Related]
4. Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.
Li X; Wang G; Sun X; Feng Y; Wang L; Sun G; Qiao H
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):155-160. PubMed ID: 38279452
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial.
Koeneman BJ; Schreibelt G; Gorris MAJ; Hins-de Bree S; Westdorp H; Ottevanger PB; de Vries IJM
Front Immunol; 2024; 15():1368103. PubMed ID: 38444861
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen.
Hao X; Zhu Y; Mu Y; Wang S; Li J; Xing P
J Cancer; 2020; 11(21):6421-6428. PubMed ID: 33033525
[No Abstract] [Full Text] [Related]
7. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).
Zinner R; Visseren-Grul C; Spigel DR; Obasaju C
Int J Oncol; 2016 Jan; 48(1):13-27. PubMed ID: 26530033
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
Kasliwal S; K R; Reddy P; Maharaj N; M G; Adhav A; Harsh K; Madnoorkar N; Diwan A; Gupta M; Patel G; J SB; Dvorkin MV
South Asian J Cancer; 2024 Jan; 13(1):66-76. PubMed ID: 38721097
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience.
Faber MG; Wang C; Kommi Reddy S; Meagher A; Early A; Chen H; Dy GK
Lung Cancer; 2022 Mar; 165():49-53. PubMed ID: 35085984
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial.
Zhao D; Li Z; Hou X; Yang L; Li Z; Yan L; Li H; Liu H; Liu X; Song F; Li G; Zhang Y; Hou X
Front Oncol; 2024; 14():1335009. PubMed ID: 38651156
[TBL] [Abstract][Full Text] [Related]
12. Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non-small cell lung cancer.
Sun R; Fei F; Wang M; Jiang J; Yang G; Yang N; Jin D; Xu Z; Cao B; Li J
Cancer Med; 2023 Sep; 12(18):19245-19259. PubMed ID: 37605514
[TBL] [Abstract][Full Text] [Related]
13. Variation of Plasma Damage-Associated Molecular Patterns in Patients with Advanced Solid Tumors after Standard of Care Systemic Treatment.
Valentí V; Capdevila L; Ruiz I; Ramos J; Badía J; Blázquez S; Villuendas Ó; Pérez C; Fernández-Sender L; Córdoba M; Alonso-Villaverde C
Cancer Invest; 2023 Dec; 41(10):821-829. PubMed ID: 37975838
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Chen B; Yao W; Li X; Lin G; Chu Q; Liu H; Du Y; Lin J; Duan H; Wang H; Xiao Z; Sun H; Liu L; Xu L; Xu Y; Xu F; Kong Y; Pu X; Li K; Wang Q; Li J; Li B; Xia Y; Wu L
Br J Cancer; 2024 Feb; 130(3):450-456. PubMed ID: 38110665
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer.
Velez M; Arango BA; Perez CA; Santos ES
Clin Med Insights Oncol; 2012; 6():117-24. PubMed ID: 22412303
[TBL] [Abstract][Full Text] [Related]
16. Experience of Autologous Immunotherapy for Non-Small Cell Lung Cancer Using Zoledronate-Actived Gammadelta T Cells.
Nguyen TT; Nguyen BT; Tran KV; Tran CK; Trinh HL; Hoang HH; Tran LM; Dao DX; Nguyen TD; Tran TH
Clin Lab; 2024 Jan; 70(1):. PubMed ID: 38213197
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy.
Mandal S; Ray B; Baniya Sharma S; Poulose J; Kasireddy V
Cureus; 2021 Sep; 13(9):e17992. PubMed ID: 34667669
[TBL] [Abstract][Full Text] [Related]
18. A long-term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non-squamous non-small cell lung cancer.
Furugen M; Shibahara D; Kiyuna T; Kami W; Miyagi K; Haranaga S; Kubota T; Matsumoto H; Yoshimi N; Fujita J
Clin Case Rep; 2021 Feb; 9(2):927-931. PubMed ID: 33598274
[TBL] [Abstract][Full Text] [Related]
19. WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer.
Nagai H; Karube R
Cureus; 2023 Oct; 15(10):e47320. PubMed ID: 38022278
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors.
Nagai H; Karube R; Zhao F
Cureus; 2023 Nov; 15(11):e48412. PubMed ID: 38074069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
